Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October.

In a mouse model of Dravet syndrome, 99% of mice treated with intracerebroventricular injection of an ASO targeting mutant sodium voltage-gated channel α subunit 1 (Nav1.1; SCN1A) survived, whereas 50% of mice treated with vehicle died...